KOD
NASDAQKodiak Sciences Inc
Price$30.05-0.90 (-2.92%)
01:30 PM07:45 PM
News · 26 weeks31-57%
2025-12-142026-06-07
Mix2090d
- SEC Filings9(45%)
- Insider5(25%)
- Other4(20%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERChief Financial Officer Borgeson John A. exercised 30,000 shares at a strike of $1.04 and sold $1,023,009 worth of shares (30,000 units at $34.10) as part of a pre-agreed trading plan (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- SECSEC Form 8-K filed by Kodiak Sciences Inc8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferencePALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 11:40am ET (8:40am PT). A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.About Kodiak Sciences Inc. Kodiak Sciences (NASDAQ:KOD) is a pr
- ANALYSTKodiak Sciences upgraded by Chardan Capital Markets with a new price targetChardan Capital Markets upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $61.00
- SECSEC Form 10-Q filed by Kodiak Sciences Inc10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsPALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."The recent positive Phase 3 GLOW2 results for Zenkuda reinforce the strength of our ABC Platform and position us to move forward on our first multi-indication BLA submission. At the same time, we are making meaningful progress across our late-stage portfolio, including continu
- PRKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesClinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia.Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies. The ABCD PlatformTM, an evolution of Kodiak's ABC platform to include conjugation of small molecules and other drugs, continues to advance as a versatile system for targeted, multi
- SECSEC Form DEFA14A filed by Kodiak Sciences IncDEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)
- SECSEC Form DEF 14A filed by Kodiak Sciences IncDEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)
- INSIDERSEC Form 4 filed by Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- SECSEC Form S-8 filed by Kodiak Sciences IncS-8 - Kodiak Sciences Inc. (0001468748) (Filer)
- SECSEC Form 10-K filed by Kodiak Sciences Inc10-K - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsPALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company's differentiated molecules, platform and long term growth strategy," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."The GLOW2 Phase 3 study delivered strong topline results showing meaningful efficacy, safety and durability of Zenkuda (tarcocimab tedromer) in
- INSIDERSEC Form 4 filed by Perlroth Victor4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- SECSEC Form 8-K filed by Kodiak Sciences Inc8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over ShamBuilding on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).Zenkuda also demonstrated superiority to sham with an 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001) and with a ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001).Zenkuda demonstrated strong efficacy independent of concomitant GLP-1 receptor agonist use. In
- INSIDERSEC Form 4 filed by Perlroth Victor4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERPerlroth Victor decreased direct ownership by 0.59% to 2,095,538 units (SEC Form 5)5 - Kodiak Sciences Inc. (0001468748) (Issuer)
- PRFinal APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI). Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothel
- PRKodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferencePALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2026, at 1:30 p.m. Pacific Time. A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event. About Kodiak Sciences Inc. Kodiak Sciences (NASDAQ:KOD) is a precommercial ret
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kodiak Sciences IncSCHEDULE 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
- INSIDERDirector Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
KOD FAQ
7 questionsWhat does Kodiak Sciences Inc do?
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific...Where does KOD stock trade?
Kodiak Sciences Inc (KOD) is listed on NASDAQ.What sector and industry is KOD in?
Kodiak Sciences Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kodiak Sciences Inc go public?
Kodiak Sciences Inc (KOD) completed its IPO in 2018.What are analysts saying about KOD?
Kodiak Sciences Inc has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy on 2026-05-11.What companies are similar to KOD?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KOD side-by-side with any of them on Quantisnow.How can I track KOD on Quantisnow?
Quantisnow aggregates Kodiak Sciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KOD to receive live email and push alerts on every new disclosure.